Cargando…

The Ovarian Cancer Tumor Immune Microenvironment (TIME) as Target for Therapy: A Focus on Innate Immunity Cells as Therapeutic Effectors

Ovarian cancer (OvCA) accounts for one of the leading causes of death from gynecologic malignancy. Despite progress in therapy improvements in OvCA, most patients develop a recurrence after first-line treatments, dependent on the tumor and non-tumor complexity/heterogeneity of the neoplasm and its s...

Descripción completa

Detalles Bibliográficos
Autores principales: Baci, Denisa, Bosi, Annalisa, Gallazzi, Matteo, Rizzi, Manuela, Noonan, Douglas M., Poggi, Alessandro, Bruno, Antonino, Mortara, Lorenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7247443/
https://www.ncbi.nlm.nih.gov/pubmed/32354198
http://dx.doi.org/10.3390/ijms21093125
_version_ 1783538155226398720
author Baci, Denisa
Bosi, Annalisa
Gallazzi, Matteo
Rizzi, Manuela
Noonan, Douglas M.
Poggi, Alessandro
Bruno, Antonino
Mortara, Lorenzo
author_facet Baci, Denisa
Bosi, Annalisa
Gallazzi, Matteo
Rizzi, Manuela
Noonan, Douglas M.
Poggi, Alessandro
Bruno, Antonino
Mortara, Lorenzo
author_sort Baci, Denisa
collection PubMed
description Ovarian cancer (OvCA) accounts for one of the leading causes of death from gynecologic malignancy. Despite progress in therapy improvements in OvCA, most patients develop a recurrence after first-line treatments, dependent on the tumor and non-tumor complexity/heterogeneity of the neoplasm and its surrounding tumor microenvironment (TME). The TME has gained greater attention in the design of specific therapies within the new era of immunotherapy. It is now clear that the immune contexture in OvCA, here referred as tumor immune microenvironment (TIME), acts as a crucial orchestrator of OvCA progression, thus representing a necessary target for combined therapies. Currently, several advancements of antitumor immune responses in OvCA are based on the characterization of tumor-infiltrating lymphocytes, which have been shown to correlate with a significantly improved clinical outcome. Here, we reviewed the literature on selected TIME components of OvCA, such as macrophages, neutrophils, γδ T lymphocytes, and natural killer (NK) cells; these cells can have a role in either supporting or limiting OvCA, depending on the TIME stimuli. We also reviewed and discussed the major (immune)-therapeutic approaches currently employed to target and/or potentiate macrophages, neutrophils, γδ T lymphocytes, and NK cells in the OvCA context.
format Online
Article
Text
id pubmed-7247443
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-72474432020-06-10 The Ovarian Cancer Tumor Immune Microenvironment (TIME) as Target for Therapy: A Focus on Innate Immunity Cells as Therapeutic Effectors Baci, Denisa Bosi, Annalisa Gallazzi, Matteo Rizzi, Manuela Noonan, Douglas M. Poggi, Alessandro Bruno, Antonino Mortara, Lorenzo Int J Mol Sci Review Ovarian cancer (OvCA) accounts for one of the leading causes of death from gynecologic malignancy. Despite progress in therapy improvements in OvCA, most patients develop a recurrence after first-line treatments, dependent on the tumor and non-tumor complexity/heterogeneity of the neoplasm and its surrounding tumor microenvironment (TME). The TME has gained greater attention in the design of specific therapies within the new era of immunotherapy. It is now clear that the immune contexture in OvCA, here referred as tumor immune microenvironment (TIME), acts as a crucial orchestrator of OvCA progression, thus representing a necessary target for combined therapies. Currently, several advancements of antitumor immune responses in OvCA are based on the characterization of tumor-infiltrating lymphocytes, which have been shown to correlate with a significantly improved clinical outcome. Here, we reviewed the literature on selected TIME components of OvCA, such as macrophages, neutrophils, γδ T lymphocytes, and natural killer (NK) cells; these cells can have a role in either supporting or limiting OvCA, depending on the TIME stimuli. We also reviewed and discussed the major (immune)-therapeutic approaches currently employed to target and/or potentiate macrophages, neutrophils, γδ T lymphocytes, and NK cells in the OvCA context. MDPI 2020-04-28 /pmc/articles/PMC7247443/ /pubmed/32354198 http://dx.doi.org/10.3390/ijms21093125 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Baci, Denisa
Bosi, Annalisa
Gallazzi, Matteo
Rizzi, Manuela
Noonan, Douglas M.
Poggi, Alessandro
Bruno, Antonino
Mortara, Lorenzo
The Ovarian Cancer Tumor Immune Microenvironment (TIME) as Target for Therapy: A Focus on Innate Immunity Cells as Therapeutic Effectors
title The Ovarian Cancer Tumor Immune Microenvironment (TIME) as Target for Therapy: A Focus on Innate Immunity Cells as Therapeutic Effectors
title_full The Ovarian Cancer Tumor Immune Microenvironment (TIME) as Target for Therapy: A Focus on Innate Immunity Cells as Therapeutic Effectors
title_fullStr The Ovarian Cancer Tumor Immune Microenvironment (TIME) as Target for Therapy: A Focus on Innate Immunity Cells as Therapeutic Effectors
title_full_unstemmed The Ovarian Cancer Tumor Immune Microenvironment (TIME) as Target for Therapy: A Focus on Innate Immunity Cells as Therapeutic Effectors
title_short The Ovarian Cancer Tumor Immune Microenvironment (TIME) as Target for Therapy: A Focus on Innate Immunity Cells as Therapeutic Effectors
title_sort ovarian cancer tumor immune microenvironment (time) as target for therapy: a focus on innate immunity cells as therapeutic effectors
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7247443/
https://www.ncbi.nlm.nih.gov/pubmed/32354198
http://dx.doi.org/10.3390/ijms21093125
work_keys_str_mv AT bacidenisa theovariancancertumorimmunemicroenvironmenttimeastargetfortherapyafocusoninnateimmunitycellsastherapeuticeffectors
AT bosiannalisa theovariancancertumorimmunemicroenvironmenttimeastargetfortherapyafocusoninnateimmunitycellsastherapeuticeffectors
AT gallazzimatteo theovariancancertumorimmunemicroenvironmenttimeastargetfortherapyafocusoninnateimmunitycellsastherapeuticeffectors
AT rizzimanuela theovariancancertumorimmunemicroenvironmenttimeastargetfortherapyafocusoninnateimmunitycellsastherapeuticeffectors
AT noonandouglasm theovariancancertumorimmunemicroenvironmenttimeastargetfortherapyafocusoninnateimmunitycellsastherapeuticeffectors
AT poggialessandro theovariancancertumorimmunemicroenvironmenttimeastargetfortherapyafocusoninnateimmunitycellsastherapeuticeffectors
AT brunoantonino theovariancancertumorimmunemicroenvironmenttimeastargetfortherapyafocusoninnateimmunitycellsastherapeuticeffectors
AT mortaralorenzo theovariancancertumorimmunemicroenvironmenttimeastargetfortherapyafocusoninnateimmunitycellsastherapeuticeffectors
AT bacidenisa ovariancancertumorimmunemicroenvironmenttimeastargetfortherapyafocusoninnateimmunitycellsastherapeuticeffectors
AT bosiannalisa ovariancancertumorimmunemicroenvironmenttimeastargetfortherapyafocusoninnateimmunitycellsastherapeuticeffectors
AT gallazzimatteo ovariancancertumorimmunemicroenvironmenttimeastargetfortherapyafocusoninnateimmunitycellsastherapeuticeffectors
AT rizzimanuela ovariancancertumorimmunemicroenvironmenttimeastargetfortherapyafocusoninnateimmunitycellsastherapeuticeffectors
AT noonandouglasm ovariancancertumorimmunemicroenvironmenttimeastargetfortherapyafocusoninnateimmunitycellsastherapeuticeffectors
AT poggialessandro ovariancancertumorimmunemicroenvironmenttimeastargetfortherapyafocusoninnateimmunitycellsastherapeuticeffectors
AT brunoantonino ovariancancertumorimmunemicroenvironmenttimeastargetfortherapyafocusoninnateimmunitycellsastherapeuticeffectors
AT mortaralorenzo ovariancancertumorimmunemicroenvironmenttimeastargetfortherapyafocusoninnateimmunitycellsastherapeuticeffectors